AI Tokens
Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Merck & Co. Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Net income (loss) from continuing operations 5,067 (1,337) (4,243) 2,962 5,787 4,429 5,085 3,744 3,161 5,461 4,767 (1,226) 4,750 (5,972) 2,825 3,018 3,252 3,949 4,307 3,824 4,571 1,214 2,749
Amortization 1,057 984 931 973 622 601 597 675 633 614 473 462 562 477 543 462 460 464 699 405 360 357 514
Depreciation 726 599 581 1,493 532 518 502 522 553 518 511 502 452 426 448 430 499 474 421 430 399 371 378
Intangible asset impairment charges — — — 55 — — — 39 — — — 779 13 — — 839 887 23 — 302 — — —
(Income) loss from investments in equity securities, net (400) (243) (168) 195 (374) (99) (90) 155 31 (57) (143) (100) 34 176 (450) 58 370 283 708 (405) (681) (280) (574)
Charge for research and development asset acquisition — 5,271 8,540 — — — — 700 2,100 — 656 — — 10,217 1,192 — — — — — — 1,556 —
Deferred income taxes (612) (544) (315) (825) (212) (448) (186) (616) (401) (181) (51) (931) (336) (355) (277) (307) (661) (262) (338) 159 (1) 11 18
Share-based compensation 369 298 185 205 204 216 195 187 195 203 176 167 164 169 145 145 139 137 120 119 117 132 111
Other 280 (81) 20 118 (51) 335 109 (101) 437 91 83 449 (99) 202 (197) 132 393 633 143 306 171 92 236
Net changes in assets and liabilities 71 423 (1,613) (2,319) 1,314 (2,259) (3,712) (1,855) 2,582 (1,012) (3,382) 144 2,177 (1,636) (2,890) (347) 263 (1,399) (1,299) (45) (139) (1,463) (2,192)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities 1,491 6,707 8,161 (105) 2,035 (1,136) (2,585) (294) 6,130 176 (1,677) 1,472 2,967 9,676 (1,486) 1,412 2,350 353 454 1,271 226 776 (1,509)
Net cash provided by operating activities 6,558 5,370 3,918 2,857 7,822 3,293 2,500 3,450 9,291 5,637 3,090 246 7,717 3,704 1,339 4,430 5,602 4,302 4,761 5,095 4,797 1,990 1,240
Capital expenditures (1,040) (893) (991) (1,033) (987) (764) (1,328) (937) (783) (791) (861) (989) (902) (965) (1,007) (1,149) (1,126) (1,129) (984) (1,208) (1,172) (986) (1,082)
Purchases of securities and other investments — (148) (374) — — (612) (595) (455) — (49) (15) (251) (117) (25) (562) (494) (5) (333) (372) — — — (1)
Proceeds from sale of Seagen Inc. common stock — — — — — — — — — — — 1,145 — — — — — — — — — — —
Proceeds from sales of securities and other investments 405 1,303 — 46 575 601 456 7 50 60 260 169 704 285 500 12 335 373 1 529 111 — 386
Acquisition of Cidara Therapeutics, Inc., net of cash acquired — — (8,779) — — — — — — — — — — — — — — — — — — — —
Acquisition of Terns Pharmaceuticals, Inc., net of cash acquired — (5,842) — — — — — — — — — — — — — — — — — — — — —
Acquisition of TARGAN, net of cash acquired (630) — — — — — — — — — — — — — — — — — — — — — —
Acquisition of Verona Pharma plc, net of cash acquired — — — (10,042) — — — — — — — — — — — — — — — — — — —
Acquisition of Eyebiotech Limited, net of cash acquired — — — — — — — — (1,344) — — — — — — — — — — — — — —
Acquisition of Elanco Animal Health Incorporated aqua business — — — — — — — (2) (1,301) — — — — — — — — — — — — — —
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired — — — — — — — — — — (746) — — — — — — — — — — — —
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical — — — — — — — — (700) — — — — — — — — — — — — — —
Acquisition of Prometheus Biosciences, Inc., net of cash acquired — — — — — — — — — — — — — (10,705) — — — — — — — — —
Acquisition of Imago BioSciences, Inc., net of cash acquired — — — — — — — — — — — — — — (1,327) — — — — — — — —
Acquisition of Acceleron Pharma Inc., net of cash acquired — — — — — — — — — — — — — — — — — — — (11,174) — — —
Acquisition of Pandion Therapeutics, Inc., net of cash acquired — — — — — — — — — — — — — — — — — — — — — (1,554) —
Other (54) (22) (66) (172) 129 5 (20) (57) 233 (289) (14) (21) (19) (33) 37 (117) (166) 12 182 (196) — (85) 11
Net cash used in investing activities (1,319) (5,602) (10,210) (11,201) (283) (770) (1,487) (1,444) (3,845) (1,069) (1,376) 53 (334) (11,443) (2,359) (1,748) (962) (1,077) (1,173) (12,049) (1,061) (2,625) (686)
Proceeds from term loan — 6,000 — — — — — — — — — — — — — — — — — — — — —
Payments on term loan — (6,000) — — — — — — — — — — — — — — — — — — — — —
Net change in short-term borrowings — (1,061) 1,061 (63) 15 48 — — — — — — (1,937) 1,937 — — — — — (3) — (4,771) 788
Proceeds from issuance of debt — 5,956 — 7,918 5,962 — — — (1) 3,600 — — (7) 5,946 — — — — — 7,936 — — —
Payments on debt — (5) (1,140) (2) (1) — (2,500) (539) — — (751) (3) (1) (1,750) (1) (1) (1,000) — (1,250) (1,166) — — (1,153)
Dividends paid to stockholders (2,099) (2,144) (2,105) (2,018) (2,031) (2,077) (2,050) (1,951) (1,953) (1,986) (1,950) (1,852) (1,855) (1,885) (1,853) (1,750) (1,747) (1,770) (1,745) (1,643) (1,649) (1,673) (1,645)
Distribution from Organon & Co. — — — — — — — — — — — — — — — — — — — — — 9,000 —
Purchases of treasury stock (653) (757) (874) (1,252) (1,323) (1,345) (1,164) (489) (444) (251) (122) (393) (466) (338) (149) — — — — (18) (583) (239) —
Proceeds from exercise of stock options 247 43 157 47 14 12 19 12 5 73 87 6 7 82 30 265 10 97 12 134 17 42 9
Other 73 (270) (80) 121 2 (194) (60) (42) (32) (220) (78) (3) (10) (234) (81) (68) 35 (104) (103) (33) (59) (97) (97)
Net cash provided by (used in) financing activities (2,432) 1,762 (2,981) 4,751 2,638 (3,556) (5,755) (3,009) (2,425) 1,216 (2,814) (2,245) (4,269) 3,758 (2,054) (1,554) (2,702) (1,777) (3,086) 5,207 (2,274) 2,262 (2,098)
Net cash provided by operating activities — — — — — — — — — — — — — — — — — — — (64) — 500 551
Net cash used in investing activities — — — — — — — — — — — — — — — — — — — — — (82) (52)
Net cash used in financing activities — — — — — — — — — — — — — — — — — — — — — (504) —
Net cash flows provided by discontinued operations — — — — — — — — — — — — — — — — — — — (64) — (86) 499
Effect of exchange rate changes on cash, cash equivalents and restricted cash (46) (37) (19) 23 10 374 156 (367) 294 (82) (138) 186 (157) (93) 87 366 (412) (309) (55) (68) (46) 78 (97)
Net increase (decrease) in cash, cash equivalents and restricted cash 2,761 1,493 (9,292) (3,570) 10,187 (659) (4,586) (1,370) 3,315 5,702 (1,238) (1,760) 2,957 (4,074) (2,987) 1,494 1,526 1,139 447 (1,879) 1,416 1,619 (1,142)

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The financial trajectory from early 2021 through late 2026 is characterized by strong operational cash generation offset by an aggressive strategic acquisition program and a consistent commitment to shareholder returns. While net income exhibits significant volatility, primarily due to large non-cash charges and R&D asset acquisitions, the net cash provided by operating activities remains generally robust, providing the primary funding source for investment and financing activities.

Operating Cash Flow Dynamics
Net income from continuing operations shows high variability, with notable contractions in June 2023, December 2023, March 2026, and June 2026. These fluctuations are largely attributed to substantial charges for research and development asset acquisitions, most notably a 10.2 billion USD charge in June 2023 and an 8.5 billion USD charge in March 2026. Despite these accounting headwinds, net cash provided by operating activities frequently exceeds net income, supported by consistent amortization and depreciation expenses, which trended upward toward 2026. Operating cash flow peaked at 9.29 billion USD in September 2024, demonstrating a strong underlying capacity to generate liquidity from core business operations.
Investment and Acquisition Strategy
Investing activities are dominated by a series of high-value acquisitions. Major capital outflows include the acquisition of Acceleron Pharma (11.17 billion USD in December 2021), Prometheus Biosciences (10.7 billion USD in June 2023), Verona Pharma (10.04 billion USD in December 2025), and Cidara Therapeutics (8.78 billion USD in March 2026). Capital expenditures have remained relatively stable, typically fluctuating between 700 million USD and 1.3 billion USD per quarter. This pattern indicates a dual-track investment strategy: maintaining existing infrastructure through steady CapEx while aggressively expanding the product pipeline through external acquisitions.
Financing and Shareholder Returns
A disciplined approach to shareholder distributions is evident through steadily increasing dividend payments, which grew from approximately 1.6 billion USD per quarter in 2021 to over 2 billion USD per quarter by 2026. Share buybacks through treasury stock purchases also accelerated over the period, with quarterly outflows increasing from a few hundred million USD in 2021 to consistently exceeding 1 billion USD in several quarters between 2024 and 2026. These activities are funded by a combination of operating cash and periodic debt issuances, such as the 7.9 billion USD issuance in December 2021 and March 2026.
Liquidity and Net Cash Positioning
The net change in cash is subject to extreme quarterly swings, reflecting the timing of multi-billion dollar acquisition payments and debt procurement. A significant liquidity event occurred in June 2021 with a 9 billion USD distribution from Organon & Co. The overall liquidity position is managed through a cycle of utilizing operating cash for dividends and CapEx, while leveraging the debt market to finance strategic mergers and acquisitions, as seen in the repeated pattern of large debt proceeds coinciding with major acquisition outflows.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?